文献速递消化道肿瘤与早癌

机器学习基因特征预测胃癌紫杉醇生存获益:SAMIT随机III期试验结果

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
PubMed 文献 · Gut · 2021-05-12

基于SAMIT 2×2析因随机III期试验的499例胃癌样本,利用定制476基因NanoString面板和随机森林机器学习模型,开发出19基因特征将患者分为紫杉醇敏感组与耐药组。在Pac-UFT验证队列中,敏感组3年DFS为66% vs 40%(HR 0.44,p=0.0029),且与治疗交互作用显著(p<0.001);外部Pac-Ram队列中敏感组中位PFS为147天 vs 112天(HR 0.48,p=0.022)。

要点

  • 19基因特征可区分胃癌患者紫杉醇敏感与耐药,为首个紫杉醇疗效预测生物标志物。
  • Pac-UFT队列中敏感组3年DFS 66% vs 40%(HR 0.44,p=0.0029),交互作用p<0.001。
  • 外部Pac-Ram队列验证敏感组中位PFS 147天 vs 112天(HR 0.48,p=0.022)。

核心结论

  • 基于SAMIT试验的机器学习模型衍生19基因特征,是首个预测胃癌紫杉醇生存获益的生物标志物。

研究设计与样本

  • SAMIT为2×2析因随机III期试验,胃癌患者根治术后随机接受Pac-S-1、Pac-UFT、S-1单药或UFT单药治疗。
  • 本研究分析499例SAMIT胃癌样本,使用定制476基因NanoString面板进行表达谱检测。
  • 采用随机森林机器学习模型在Pac-S-1训练队列中开发基因特征,Pac-UFT队列验证,外部Pac-Ram转移性胃癌队列作为外部验证。

主要发现

  • 随机森林模型从Pac-S-1训练队列生成19基因特征,将患者分为Pac-Sensitive和Pac-Resistant两组。
  • Pac-UFT验证队列中,Pac-Sensitive患者3年DFS为66% vs 40%(HR 0.44,p=0.0029)。
  • UFT或S-1单药组中Pac-Sensitive与Pac-Resistant无生存差异,交互作用检验p<0.001。
  • 外部Pac-Ram验证队列中,该特征预测Pac-Sensitive患者获益(中位PFS 147天 vs 112天,HR 0.48,p=0.022)。

关键数值与推荐

  • 19基因特征将患者分为Pac-Sensitive与Pac-Resistant两组。
  • Pac-UFT队列:3年DFS 66% vs 40%(HR 0.44,p=0.0029)。
  • 单药组交互作用检验p<0.001。
  • 外部Pac-Ram队列:中位PFS 147天 vs 112天(HR 0.48,p=0.022)。

临床怎么用

  • 该19基因特征可用于筛选可能从紫杉醇化疗中获益的胃癌患者,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To date, there are no predictive biomarkers to guide selection of patients with gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) was a 2×2 factorial randomised phase III study in which patients with GC were randomised to Pac-S-1 (paclitaxel +S-1), Pac-UFT (paclitaxel +UFT), S-1 alone or UFT alone after curative surgery. DESIGN: The primary objective of this study was to identify a gene signature that predicts survival benefit from paclitaxel chemotherapy in GC patients. SAMIT GC samples were profiled using a customised 476 gene NanoString panel. A random forest machine-learning model was applied on the NanoString profiles to develop a gene signature. An independent cohort of metastatic patients with GC treated with paclitaxel and ramucirumab (Pac-Ram) served as an external validation cohort. RESULTS: From the SAMIT trial 499 samples were analysed in this study. From the Pac-S-1 training cohort, the random forest model generated a 19-gene signature assigning patients to two groups: Pac-Sensitive and Pac-Resistant. In the Pac-UFT validation cohort, Pac-Sensitive patients exhibited a significant improvement in disease free survival (DFS): 3-year DFS 66% vs 40% (HR 0.44, p=0.0029). There was no survival difference between Pac-Sensitive and Pac-Resistant in the UFT or S-1 alone arms, test of interaction p<0.001. In the external Pac-Ram validation cohort, the signature predicted benefit for Pac-Sensitive (median PFS 147 days vs 112 days, HR 0.48, p=0.022). CONCLUSION: Using machine-learning techniques on one of the largest GC trials (SAMIT), we identify a gene signature representing the first predictive biomarker for paclitaxel benefit. TRIAL REGISTRATION NUMBER: UMIN Clinical Trials Registry: C000000082 (SAMIT); ClinicalTrials.gov identifier, 02628951 (South Korean trial).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut. 2021. PMID: 33980610. doi:10.1136/gutjnl-2021-324060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。